MedTrace Logo

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05252416 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-28

No results posted yet for this study

Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.

Conditions

Interventions

DRUG

BLU-222

Oral administration

DRUG

Carboplatin

IV Infusion

DRUG

Ribociclib

Oral administration

DRUG

Fulvestrant

Intra muscular administration

Sponsors & Collaborators

  • Blueprint Medicines Corporation

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-07
Primary Completion
2025-07-04
Completion
2025-07-04
FDA Drug
Yes

Countries

  • United States
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05252416 on ClinicalTrials.gov